Endostatin Induces Endothelial Cell Apoptosis

Mohanraj Dhanabal, Ramani Ramchandran, Matthew J.F. Waterman, Hua Lu, Bertrand Knebelmann, Mark S. Segal, Vikas P. Sukhatme

Journal of Biological Chemistry · 1999 · 584 citations · 18 references

DOIFull text

Open access

Concepts

Abstract

Endostatin, a carboxyl-terminal fragment of collagen XVIII, has been shown to regress tumors in mice. In this study, we have analyzed the mechanism of endostatin action on endothelial cells and nonendothelial cells. Endostatin treatment of cow pulmonary artery endothelial cells caused apoptosis, as demonstrated by three methods, annexin V-fluorescein isothiocyanate staining, caspase 3, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end-labeling assay. Moreover, addition of endostatin led to a marked reduction of the Bcl-2 and Bcl-XLanti-apoptotic protein, whereas Bax protein levels were unaffected. These effects were not seen in several nonendothelial cells. Collectively, these findings provide important mechanistic insight into endostatin action. Endostatin, a carboxyl-terminal fragment of collagen XVIII, has been shown to regress tumors in mice. In this study, we have analyzed the mechanism of endostatin action on endothelial cells and nonendothelial cells. Endostatin treatment of cow pulmonary artery endothelial cells caused apoptosis, as demonstrated by three methods, annexin V-fluorescein isothiocyanate staining, caspase 3, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end-labeling assay. Moreover, addition of endostatin led to a marked reduction of the Bcl-2 and Bcl-XLanti-apoptotic protein, whereas Bax protein levels were unaffected. These effects were not seen in several nonendothelial cells. Collectively, these findings provide important mechanistic insight into endostatin action. fluorescein isothiocyanate fluorescence-activated cell sorting terminal deoxynucleotidyl transferase-mediated dUTP nick-end-labeling tumor necrosis factor Dulbecco's modified Eagle's medium cow pulmonary artery endothelial phosphate-buffered saline propidium iodide fibroblast growth factor phosphatidylserine fetal calf serum Angiogenesis is required for tumors to grow beyond a few millimeters in size (1Folkman J. Merler E. Abernathy C. Williams G. J. Exp. Med. 1971; 133: 275-288Crossref PubMed Scopus (1345) Google Scholar). Advantages of anti-angiogenic therapy include ease of access of drugs to the endothelial cell compartment, targeting of a genetically stable cell population (endothelial versustumor cells) thereby lessening the chance of drug resistance and “amplification” achieved, because one endothelial cell supports the growth of 50–100 tumor cells (2O'Reilly M.S. Holmgren L. Shing Y. Chen C. Rosenthal R.A. Moses M. Lane W.S. Cao Y. Sage E.H. Folkman J. Cell. 1994; 79: 315-328Abstract Full Text PDF PubMed Scopus (3172) Google Scholar, 3Thorpe P.E. Burrows F.J. Breast Cancer Res. Treat. 1995; 36: 237-251Crossref PubMed Scopus (119) Google Scholar, 4Fan T.P. Jaggar R. Bicknell R. Trends Pharmacol. Sci. 1995; 16: 57-66Abstract Full Text PDF PubMed Scopus (214) Google Scholar, 5Baillie C.T. Winslet M.C. Bradley N.J. Br. J. Cancer. 1995; 72: 257-267Crossref PubMed Scopus (102) Google Scholar, 6Bicknell R. Ann. Oncol. 1994; 5 Suppl. 4: 45-50Abstract Full Text PDF PubMed Scopus (44) Google Scholar, 7Burrows F.J. Thorpe P.E. Pharmacol. Ther. 1994; 64: 155-174Crossref PubMed Scopus (125) Google Scholar). Fragments of proteins have recently been described with anti-angiogenic action. Endostatin, a 20-kDa C-terminal fragment of collagen XVIII, is a specific inhibitor of endothelial cell proliferation (8O'Reilly M.S. Boehm T. Shing Y. Fukai N. Vasios G. Lane W.S. Flynn E. Birkhead J.R. Olsen B.R. Folkman J. Cell. 1997; 88: 277-285Abstract Full Text Full Text PDF PubMed Scopus (4253) Google Scholar), migration (9Dhanabal M. Ramchandran R. Volk R. Stillman I.E. Lombardo M. Arispe L. Simons M. Sukhatme V.P. Cancer Res. 1999; 59: 189-197PubMed Google Scholar), and angiogenesis (8O'Reilly M.S. Boehm T. Shing Y. Fukai N. Vasios G. Lane W.S. Flynn E. Birkhead J.R. Olsen B.R. Folkman J. Cell. 1997; 88: 277-285Abstract Full Text Full Text PDF PubMed Scopus (4253) Google Scholar). Endostatin regresses established syngeneic Lewis lung carcinomas, T241 fibrosarcoma, and B16 melanoma tumors in xenograft models (8O'Reilly M.S. Boehm T. Shing Y. Fukai N. Vasios G. Lane W.S. Flynn E. Birkhead J.R. Olsen B.R. Folkman J. Cell. 1997; 88: 277-285Abstract Full Text Full Text PDF PubMed Scopus (4253) Google Scholar). Recently, tumor dormancy was induced following repeated cycles of endostatin treatment (10Boehm T. Folkman J. Browder T. O'Reilly M.S. Nature. 1997; 390: 404-407Crossref PubMed Scopus (1612) Google Scholar). Administration of recombinant mouse endostatin to tumor-bearing animals increases the apoptotic index of the tumor cells without affecting their proliferation index (8O'Reilly M.S. Boehm T. Shing Y. Fukai N. Vasios G. Lane W.S. Flynn E. Birkhead J.R. Olsen B.R. Folkman J. Cell. 1997; 88: 277-285Abstract Full Text Full Text PDF PubMed Scopus (4253) Google Scholar), but no data on endothelial cells has been described. The mechanism of endostatin action is unknown. In vitroresults from this laboratory and others (8O'Reilly M.S. Boehm T. Shing Y. Fukai N. Vasios G. Lane W.S. Flynn E. Birkhead J.R. Olsen B.R. Folkman J. Cell. 1997; 88: 277-285Abstract Full Text Full Text PDF PubMed Scopus (4253) Google Scholar, 9Dhanabal M. Ramchandran R. Volk R. Stillman I.E. Lombardo M. Arispe L. Simons M. Sukhatme V.P. Cancer Res. 1999; 59: 189-197PubMed Google Scholar) show that endostatin inhibits the proliferation of endothelial cells but has no effect on tumor cells or nonendothelial cell types, including fibroblasts and smooth muscle cells. Thus, the action of endostatin seems to be endothelial cell specific. Because the presence of endostatin in endothelial cell culture affects proliferation (and migration), we asked whether the endothelial cells are undergoing programmed cell death. Our studies show that soluble yeast-derived mouse endostatin altered the morphology of endothelial cells leading to the characteristic features of cells undergoing apoptosis. Endostatin-treated cells shifted in annexin V-FITC1-labeling by FACS, and after roughly 12 h, externalization of phosphatidylserine on the cell surface ensued. In addition, endostatin treatment increased the activity of the intracellular protease caspase 3, resulting in DNA degradation in the nucleus, as independently confirmed via the terminal deoxynucleotidyl transferase-mediated dUTP nick-end-labeling) (TUNEL) assay. Western blot analysis showed reduction of the Bcl-2 and Bcl-XL anti-apoptotic proteins without any effect on the level of the Bax pro-apoptotic protein. In nonendothelial cells,viz., NIH3T3 and A10 smooth muscle cells, endostatin did not show any effects in any of the above assays, indicating specificity of endostatin toward endothelial cells. The mouse endostatin protein was produced and purified from yeast, as described elsewhere (9Dhanabal M. Ramchandran R. Volk R. Stillman I.E. Lombardo M. Arispe L. Simons M. Sukhatme V.P. Cancer Res. 1999; 59: 189-197PubMed Google Scholar). Some batches contained DNA, which had no effect on apoptosis. Anti-Fade reagent was purchased from Molecular Probes, Inc. Tumor necrosis factor(TNF)-α was obtained from R & D Systems, Inc. 16% methanol-free formaldehyde, used for the fixing solutions, was purchased from Polysciences, Inc. The annexin V-FITC-labeling kit was purchased fromCLONTECH. Cow pulmonary artery endothelial (C-PAE) cells, obtained from ATCC (Manassas, VA), were maintained in DMEM supplemented with 10% fetal calf serum, 100 units/ml penicillin, 100 μg/ml streptomycin, and 2 mml-glutamine. The cells were incubated in a humidified environment at 37 °C in the presence of 5% CO2. Bovine aortic endothelial cells, a gift from C. Ferran, Beth Israel Deaconess Medical Center, Boston, were maintained in DMEM containing 10% fetal calf serum. Bovine adrenal cortex capillary endothelial cells were a gift from Dr. J. Folkman, Children's Hospital, Boston. HUVE and HMVE-L cells were obtained from Clonetics Corp. (San Diego, CA). IMR-90, lung fibroblast, NIH3T3 fibroblast, A10 smooth muscle cell, H9c2 (2-1)-myoblast cell line, and 786–0 renal clear cell carcinoma cells were all purchased from ATCC. Annexin V, a calcium-dependent phospholipid-binding protein with a high affinity for phosphatidylserine (PS) was used to detect early stage apoptosis (11van Engeland M. Nieland L.J. Ramaekers F.C. Schutte B. Reutelingsperger C.P. Cytometry. 1998; 31: 1-9Crossref PubMed Scopus (1544) Google Scholar). Briefly, 200,000 cells were plated onto a fibronectin-coated 6-well plate in DMEM containing 2% FCS and 3 ng/ml bFGF. Different concentrations of recombinant mouse endostatin were added to each well, and cells were harvested and processed 18 h after treatment. For the time course study, 10 μg/ml endostatin was added and cells were processed after 3, 4, 6, 12, and 18 h. Human recombinant TNF-α (40 ng/ml) was used as a positive control. The cells were washed in PBS and resuspended in binding buffer (10 mm HEPES/NaOH, pH 7.4, 140 mm NaCl, 2.5 mm CaCl2). Annexin V-FITC was added to a final concentration of 100 ng/ml, and the cells were incubated in the dark for 10 min, then washed again in PBS and resuspended in 300 μl of binding buffer. 10 μl of propidium iodide (PI) was added to each sample before flow cytometric analysis. The cells were analyzed using a Becton Dickinson FACStar plus flow cytometer. Electronic compensation was used to eliminate bleed-through fluorescence. In each sample, a minimum of 10,000 cells was counted and stored in listmode. Data analysis was performed with standard Cell Quest software (Becton-Dickinson). The quadrant settings were set so that the negative control allowed less than 1% positivity. Endostatin was added to nonendothelial cells (NIH3T3 and 786–0) at 10 μg/ml, and the cells were processed and analyzed as described above. This assay was performed in a 75-cm2 tissue culture flask or on fibronectin-coated 6-well plates. For the 6-well plates, 0.5–1 × 106 cells (75-cm2 flask, 2 × 106 cells) were seeded and maintained overnight in DMEM with 10% FCS. The following day, the old medium was replaced with fresh medium (2% FCS), and the cells were incubated overnight at 37 °C. Following starvation, the cells were stimulated with bFGF (3 ng/ml) in DMEM (2% FCS). Along with bFGF, yeast endostatin (10 μg/ml, final concentration) was added, and the cells were grown for 24 h. For the control plate, only the PBS buffer was added. As a positive control, TNF-α was used at a final concentration of 20 ng/ml. After 24 h, the supernatant cells were centrifuged and collected. The wells (flasks) were trypsinized to collect the attached cells and combined with the supernatant cells. The cells were counted and resuspended in cell lysis buffer (CLONTECH) at a concentration of 4 × 107 cells/ml. The rest of the protocol followed the manufacturer's instruction (CLONTECH). A specific inhibitor of caspase 3, DEVD-fmk, was used to confirm the specificity as suggested by the manufacturer. The absorbance was measured in a microplate reader (Bio-Rad) at 405 nm. Fold-increase in protease activity (caspase 3) was determined by comparing the results of the induced sample (yeast endostatin or TNF-α) with the uninduced control. Similarly nonendothelial cells (NIH3T3 and H9c2 (2-1)-myoblast) were used and analyzed as described above. C-PAE cells were seeded at a density of 5,000 cells/well on fibronectin-coated (10 μg/ml) Lab-Tek chamber slides and grown in 0.4 ml of DMEM with 10% FCS. After 2 days, the old medium was aspirated and fresh DMEM with 2% FCS was added, and the cells were starved overnight. The following day, 0.36 ml of new medium (with 2% FCS) containing 3 ng/ml bFGF was added along with yeast endostatin (10 μg/ml) or TNF-α (20 ng/ml). For control samples, fresh medium (2% FCS) containing bFGF (3 ng/ml) was added. Following induction (24 h), the slides were washed twice with PBS, and subsequently fixed in fresh 4% formaldehyde/PBS at 4 °C for 25 min. The slides were washed in PBS and the cells permeabilized in 0.2% Triton X-100/PBS for 5 min on ice, then washed with fresh PBS twice for 5 min each at room temperature, and the TUNEL assay was performed as described below. The TUNEL assay was performed as described in the ApoAlert DNA fragmentation assay kit user manual (CLONTECH), except that the final concentration of propidium iodide (Sigma) used was 1 μg/ml. After the assay, a drop of anti-fade solution was added, and the treated portion of the slide was covered with a glass coverslip with the edges sealed with clear nail polish. Slides were viewed immediately under a fluorescent microscope using a dual filter set for green (520 nm) and red fluorescence (>620 nm). The images were captured using a digital microscope (Nikon Microphot-SA) and processed using SPOT software version 1.1.02. For all samples except the positive control (TNF-α: 5 fields), 15 random fields were chosen, and the number of green and red cells per field were counted. Floating cells were collected by centrifugation at 300 × g for 10 min at 4 °C. The old medium was aspirated, and the cells were resuspended in 500 μl of PBS (pH 7.4). Cells were centrifuged again, the PBS removed, and the pellet was resuspended in 75 μl of fresh PBS. Resuspended cells were spread on a poly-l-lysine-coated slide (Labscientific, Inc.) using a clean slide. The cells were fixed by immersing the slides in fresh 4% formaldehyde/PBS at 4 °C for 25 min. The rest of the protocol was carried out as explained above. C-PAE cells (1 × 106) were seeded in 10-cm Petri dishes precoated with fibronectin (10 μg/ml) in the presence of 2% FCS containing 3 ng/ml bFGF. Endostatin was added at 10 μg/ml, and cells were harvested at 12, 24, and 28 h after treatment. Cells were washed three times in PBS buffer, pH 7.4, and the cells were resuspended in 1 ml of 1× EBC buffer (50 mm Tris-HCl, pH 8.0, 120 mm NaCl, 1% Nonidet P-40) containing freshly added complete protease inhibitor tablet (Boehringer Mannheim), 100 μg/ml Pefabloc, 1 μg/ml pepstatin. The protein concentration in whole cell lysate was measured by the bicinchoninic acid method. 30 μg of whole cell extract was loaded onto a 4–15% gradient polyacrylamide gel. Transfer was performed using a semi-dry transblot apparatus (Bio-Rad). The membrane was blocked in wash buffer (1× Tris-buffered saline) with 5% nonfat dry milk and incubated at 37 °C for 1 h. Goat antibody directed against human Bcl-2 (N-19) {sc-492-G} was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Affinity purified mouse polyclonal antibody against Bax (B-9) {sc7490} and Bcl-XS/L {sc1690} were purchased from the same manufacturer. Polyclonal anti-actin antibody (Sigma) was used to normalize for protein loading. Secondary antibodies were anti-goat, mouse and rabbit immunoglobulin conjugated to horseradish peroxidase (Amersham Pharmacia Biotech). The immunoreactivity was detected with an enhanced chemiluminescence reagent (Pierce). Images were scanned using a flat bed scanner (Scan-Jet 4C) and quantitated by the NIH image 1.61 software. Normalization was done by dividing the Bcl-2 signal by that of actin within each experiment. When proliferating, C-PAE cells were treated with mouse endostatin at a concentration of 10 μg/ml, the cells rounded (Fig.1 A) and detached from the fibronectin-coated plate. In the controls, the cells showed intact endothelial cell morphology, whereas endostatin-treated cells appeared rounded and showed membrane blebbing characteristic of apoptotic cells. We have also observed similar effects with endostatin-treated bovine adrenal cortex capillary endothelial and bovine aorta endothelial cells (data not shown), but C-PAE cells showed the most dramatic effect. Interestingly, these effects of endostatin were most pronounced when bFGF was added to subconfluent monolayers (2 × 104/well in a 24-well plate and × in a 6-well when cells were in the in endostatin to be for tumor is endothelial cell endostatin at 10 μg/ml on nonendothelial cells, A10 and H9c2 did not show any effect as was seen in endothelial cells and Moreover, because cells plated on fibronectin-coated in the presence of effect was not via we for of apoptosis, phosphatidylserine intracellular protease and with DNA After of apoptosis, most cell the membrane from the surface of the membrane to the (11van Engeland M. Nieland L.J. Ramaekers F.C. Schutte B. Reutelingsperger C.P. Cytometry. 1998; 31: 1-9Crossref PubMed Scopus (1544) Google Scholar, G. G. 1997; PubMed Scopus Google Scholar, G. Reutelingsperger C.P. 1994; PubMed Google Scholar). be detected by with an of annexin V, protein that to programmed cell externalization membrane and DNA fragmentation G. G. 1997; PubMed Scopus Google Scholar). 2 A annexin V-FITC in with in C-PAE cells treated for 18 h with concentrations of Endostatin at 10 μg/ml showed a in annexin fluorescence The fluorescence control and endostatin-treated cell was at 5 and 10 μg/ml. The in fluorescence was similar for endostatin at 10 μg/ml and the positive control TNF-α (40 ng/ml). of endostatin μg/ml did not show any annexin (data not the time at which endostatin caused externalization of we a time course 2 The effect of endostatin was at 12 h after treatment. before h did not show a control and treated of samples with fluorescence showed annexin to the cell membrane at 12 h with no in the (data not this the of the cells were negative for the early stage of apoptosis. increased time h), in addition to membrane with annexin of the cells positive for (data not G. G. 1997; PubMed Scopus Google Scholar, C. Reutelingsperger C. J. 1995; PubMed Scopus Google Scholar), with a stage of apoptosis. levels of annexin were observed in endothelial cell bovine aorta endothelial and bovine adrenal cortex capillary endothelial (data not We have also the effect of human endostatin on these three bovine endothelial cell We to detect annexin in the presence of human endostatin added to these cells, whereas when human endothelial cell were used and in a marked in annexin fluorescence. R. R. M. and in These data that apoptosis, as by annexin staining, in endothelial cells in to mouse and human to nonendothelial cells, 786–0 and NIH3T3 cells, we to any annexin In addition, we nonendothelial cells and H9c2 (2-1)-myoblast) and no effect of endostatin (data not on these action to be for endothelial cells. 3 is an intracellular protease early apoptosis of cells and by specific and DNA proteins G. G. 1997; PubMed Scopus Google C. Reutelingsperger C. J. 1995; PubMed Scopus Google Scholar, Cell. 1997; Full Text Full Text PDF PubMed Scopus Google Scholar, L. T. J. Exp. Med. PubMed Scopus Google Scholar). This protease activity be measured by of the after from the we performed a time course with 10 μg/ml of endostatin and for in caspase 3 was no in caspase 3 activity the treated and the control samples at 4, and h (data not caspase 3 activity was 24 h after treatment with endostatin The caspase activity of the endostatin and TNF-α treated samples is shown in 3 When with controls, endostatin-treated cells showed a in caspase 3 activity after 24 h, whereas TNF-α a When a specific inhibitor of caspase 3 was in the same samples, the protease activity was at of the dark with the indicating that the in the measured activity was specific for caspase For NIH3T3 cells a in caspase 3 was whereas in cells was no in caspase 3 levels treated and control of DNA is one of the in the of an apoptotic A TUNEL assay was performed on and control cells. 4 A the of cells on In the presence of the terminal and slides showed positive cells under green fluorescence and h), whereas no positive cells were seen in the control the the endostatin-treated slide showed cell fluorescence and g the same field of cells with propidium We counted the number of apoptotic cells in several and the of apoptotic cells by the number of red cells per is in 4 B. The apoptosis in the control cells was In the endostatin-treated cells, a in the apoptosis was observed in cells whereas a was observed in the attached cells the apoptosis was In the of in the bovine adrenal cortex capillary endothelial cells was 2% when with the control cells a L. M. N. B. B. O'Reilly M. Folkman J. Sci. 1998; PubMed Scopus Google Scholar), that endostatin is a apoptotic than as Bcl-2 and Bcl-XL programmed cell in to Res. 1998; PubMed Scopus Google Scholar, Cell Sci. 1998; PubMed Scopus Google Scholar). pro-apoptotic proteins as Bax and cell and in are to apoptosis of Cell Sci. 1998; PubMed Scopus Google Scholar). We whole cell extract of endostatin-treated and control C-PAE cells for Bcl-2 and Bax In growth C-PAE cells, Bcl-2 was was to 28 in endostatin-treated cells showed a marked in Bcl-2 5 that the levels of Bcl-2 with control was and less at 12, 24, and 28 h, after with actin levels used as In Bax was similar control and treated 5 Bcl-2 protein was not detected in NIH3T3 and cells. Bax levels were not by endostatin treatment in these cell 6, A In C-PAE cells, at the early time h), Bcl-XL level was by whereas was in NIH3T3 cell 6, and Interestingly, we have detected only the pro-apoptotic of in whereas and were detected in These findings that endostatin activity by Bcl-2 Interestingly, endothelial growth factor has been shown to Bcl-2 levels in endothelial cells N. J. 1998; Full Text Full Text PDF PubMed Scopus Google Scholar). Because endostatin effects (data not shown), Bcl-2 to be one of studies that the Bcl-2 protein to as and which cell 1998; PubMed Scopus Google Scholar, 1997; Full Text Full Text PDF PubMed Google Scholar). The of Bcl-2 Cell. Full Text PDF PubMed Scopus Google Scholar). Bcl-2 and Bcl-XL with Bax Nature. 1994; PubMed Scopus Google E. Sci. 1995; PubMed Scopus Google Scholar) and of Bax apoptosis Cell. Full Text PDF PubMed Scopus Google Scholar). Recently, was shown that endothelial cell apoptosis by and 1995; PubMed Scopus Google Scholar). In study, we did in Bcl-2 (and in endostatin-treated but no in Bax is that Bcl-2 independently of as has been shown for cells 1995; PubMed Scopus Google Scholar). are in to the of anti-apoptotic and pro-apoptotic proteins and their in to endostatin treatment. In we have demonstrated that endostatin apoptosis of endothelial cells in but not nonendothelial cells. This the mechanistic insight into the action of The intracellular that the apoptotic are under We Dr. for of the digital and Dr. M. for in cell

References

18